Orchestrating the Next Era of Decentralized and Automated Bioprocessing

As we move into mid-2026, the biopharmaceutical industry is recalibrating to balance scientific innovation with the operational discipline required for patient safety. In this issue, we examine how decentralization and digital automation are becoming the new standard for manufacturing resilience and global clinical success.

Our cover story, “Getting to the Point of Care,” explores the shift from centralized production to personalized bedside manufacturing. By producing therapies directly at hospitals or pharmacies, we simplify logistics and drastically shorten delivery times. This agility is further supported by the industrialization of viral vector production. In “How Automation Is Improving AAV Purification,” we see how automated density gradient systems slash processing times by 75%. Such efficiency is vital as the adeno-associated virus market scales toward an estimated $107.2 billion by 2035.¹

However, operational excellence also hinges on solving “QC Bottlenecks.” As manufacturing scales, quality control must move away from artisanal manual workflows. True scalability requires a systems-thinking redesign of lab architecture, integrating fragmented data streams across laboratory information management systems and manufacturing execution systems to reduce coordination overhead.

Finally, global expansion remains a priority. “Tailoring Strategies to APAC’s Diverse Clinical Trial Environment” highlights the region's immense recruitment potential. Success in that region requires more than a copy/paste strategy; sponsors must navigate diverse regulatory pathways and build the local trust essential for high-quality execution.

Together, these advancements reflect an industry leaning into technical maturity while remaining grounded in the operational discipline required for stability.

Reference

1. Adeno-Associated Virus Gene Therapy Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035. IMARC Group. Accessed May 20, 2026. https://www.imarcgroup.com/adeno-associated-virus-gene-therapy-market